Trevi Therapeutics: Fidelity Buys 8.8% After Q2 Miss
Trevi Therapeutics posted a second consecutive EPS miss in Q2 2026 while FMR LLC disclosed an 8.8% ownership stake, with institutional investors collectively holding 107.7% of the outstanding float in
Trevi Therapeutics Misses Q2 as New Cough Trial Begins
NEW YORK, August 21 —
Trevi Therapeutics, Inc. (TRVI) has now missed earnings estimates in consecutive quarters, yet Fidelity Investments just disclosed an 8.8% ownership stake in a company whose lead drug Haduvio has never treated a commercial patient. The gap between what professional money expects and what the financials show will narrow, or widen, when a key cough trial readout arrives.
- Q2 EPS of -$0.11 missed consensus by 0.9%; Q1 missed by -27.4%, two consecutive misses following two consecutive beats
- $320M cash, zero long-term debt; annual operating cash outflow of $53M
- Analyst consensus price target $28.18 vs current $18.25; short interest at 10.2% of float
The Conviction Trade
Trevi Therapeutics develops Haduvio, an oral extended-release formulation of nalbuphine, targeting chronic cough in idiopathic pulmonary fibrosis (IPF), a progressive lung disease where no approved therapy addresses the debilitating cough. Institutional investors collectively hold 107.7% of the outstanding float, a figure that reflects both deep conviction and substantial lending to short sellers. FMR LLC's amended 13G disclosed an 8.8% stake approximately two weeks ago. The analyst consensus price target of $28.18 against a current price of $18.25 signals that professional forecasters expect significant appreciation, with JonesTrading adding a strong call of its own recently.
Two Misses, One Pattern
The earnings trajectory complicates the bull case without breaking it. Two consecutive EPS beats preceded the current streak: -$0.06 versus -$ four quarters ago, then -$0.08 versus -$ the following quarter. Since then, Q1 2026 missed by -27.4% and Q2 missed by a narrower 0.9%, per the August 6 earnings filing. For a company with no revenue, the misses simply reflect rising trial expenditures. The $320 million cash reserve against a $53 million annual operating outflow provides more than six years of runway at current burn, a horizon suggesting that a risk-adjusted DCF on the IP, not the quarterly burn, drives institutional thinking.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| TRVI | $2.6B | n/a | +143.7% |
| FULC | $294M | n/a | -41.0% |
| XFOR | $400M | n/a | +2.8% |
| VRCA | $83M | n/a | -11.1% |
| STOK | $2.0B | n/a | +60.5% |
| TARA | $230M | n/a | +25.8% |
The CRISP Trial Is the Only Real Catalyst
The next inflection point is clinical. Trevi's Phase 2b CRISP trial for chronic cough in IPF received FDA clearance to advance to Phase 3 roughly five months ago. A newly launched Phase 2a trial targets refractory chronic cough in approximately 2-3 million US patients. Together, the two trials define the near-term catalyst calendar. A CRISP readout will set the terms of the next debate: positive data would give bulls a hard number to underwrite the $28.18 consensus target, while disappointment would vindicate the 10.2% short interest concentrated against a pre-revenue company. Run the free Trevi Therapeutics, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What were Trevi Therapeutics' Q2 2026 earnings?
Trevi Therapeutics reported a Q2 2026 EPS of negative $0.11, missing consensus estimates by 0.9%. This follows a Q1 2026 miss of 27.4%, marking two consecutive misses after two prior consecutive beats.
What is the CRISP trial for chronic cough in IPF?
The CRISP trial is Trevi Therapeutics' Phase 2b study of Haduvio, an oral extended-release formulation of nalbuphine, targeting chronic cough in idiopathic pulmonary fibrosis. The trial received FDA clearance to advance to Phase 3 approximately five months before this report, making its readout the primary near-term catalyst for the stock.
What stake did Fidelity disclose in Trevi Therapeutics?
FMR LLC disclosed an 8.8% ownership stake in Trevi Therapeutics via an amended 13G filing approximately two weeks before this report. Institutional investors as a group hold 107.7% of the outstanding float, a figure the article attributes to deep conviction combined with substantial share lending to short sellers.
How much cash does Trevi Therapeutics have?
Trevi Therapeutics holds $320 million in cash with zero long-term debt. At an annual operating cash outflow of $53 million, that reserve provides more than six years of runway at the current burn rate.
What is Trevi Therapeutics' analyst price target?
The analyst consensus price target for Trevi Therapeutics is $28.18, compared to a current price of $18.25 at the time of this report. JonesTrading has added a strong call of its own recently, while short interest stands at 10.2% of the float.
Trevi Therapeutics missed EPS estimates for the second consecutive quarter in its August 6, 2026 earnings 8-K, yet FMR LLC (Fidelity) just disclosed an 8.8% ownership stake and JonesTrading is forecasting strong price appreciation. The company has no revenue, burns $53 million per year in operating cash, and just launched a new chronic cough trial targeting approximately 2-3 million patients — setting up a stark divide between institutional bulls and short sellers who hold 10.2% of the float.